Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1Phase 1/2 1

Status

Recruiting 5Not yet recruiting 2Active not recruiting 2

Sponsor Class

INDUSTRY 3OTHER 1NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 4Lymphoid 1

Conditions

Multiple Myeloma 3Smoldering Multiple Myeloma 1Recurrence 1Lymphoma, Non-Hodgkin 1

Interventions

Specimen Handling 125pembrolizumab 123Magnetic Resonance Spectroscopy 108Carboplatin 89Cyclophosphamide 80Biopsy 69Cisplatin 67Paclitaxel 61Bevacizumab 56Gemcitabine 54Nivolumab 49fludarabine 48Dexamethasone 41Rituximab 39Pemetrexed 39Fluorouracil 39Radiotherapy 37Doxorubicin 37atezolizumab 36Docetaxel 36Leucovorin 35Oxaliplatin 32Capecitabine 32venetoclax 31Temozolomide 29Prednisone 29durvalumab 27Standard of Care 27Radiation 27Letrozole 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × iberdomide × 30 days × Clear all
NCT05583617 2026-06-03

PLYCOM

Hoffmann-La Roche

Phase 1/2 Recruiting
200 enrolled
Plasma cell

Multiple Myeloma

NCT04776395 2026-06-01

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

Emory University

Phase 2 Recruiting
68 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT06465316 2026-05-27

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Recruiting
26 enrolled
Plasma cell

Multiple Myeloma

NCT06215118 2026-05-22

MagnetisMM-30

Pfizer

Phase 1 Recruiting
87 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT05169515 2026-05-18

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Hoffmann-La Roche

Phase 1 Recruiting
121 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡